Shannon is developing novel immunomodulatory fusion proteins (IFPs) as an engineering strategy to enable T cells to overcome inhibitory obstacles in the tumor microenvironment. She is examining how IFP expression impacts T cell programming, including improved metabolism and resistance to exhaustion, and has shown significantly enhanced primary human T cell function and outcomes in hematological and solid tumor models.
Tom is generating and optimizing expression vectors encoding high affinity WTI-specific TCR genes for use in T cell therapy trials. He is also developing novel methods for the directed evolution of tumor specific TCRs in vitro.
Rachel is developing high affinity TCRs for immunotherapy of acute myeloid leukemia and pancreatic, lung, ovarian and other cancers. She has identified several effective TCRs targeting KRAS and cyclin A1, presented by multiple HLA alleles, thus creating an immunotherapy “toolbox” for clinical use.
Kristin studies properties of T cell migration and tumor microenvironments that impact the utility of adoptive T cell therapy for solid tumors, with a focus on ovarian cancer. Chemotherapy, immune checkpoint blockade, cell depletion techniques, and abrogation of other negative T cell regulators are being tested as strategies that might enhance adoptive T cell immunotherapy efficacy.
Leah is using autochthonous mouse models of cancer to test strategies for improving the efficacy of adoptive immunotherapies.
Tijana is developing T cell strategies to effectively target and destroy cancerous cells in mouse models of multiple myeloma.
Ashley is using genome editing and synthetic biology approaches to enhance T cell fitness for targeting solid tumors.